Mark Baker

1.9k citations

22 papers · 757 indexed · h-index 14

Impact in

Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
Public Health, Environmental and Occupational Health top 5%
- Malaria Research and Control
- Mosquito-borne diseases and control

Papers in ⓘ

Public Health, Environmental and Occupational Health 11
- Malaria Research and Control 10
Infectious Diseases 7
- HIV/AIDS drug development and treatment 6
- HIV/AIDS Research and Interventions 5

Co-authors: Martina Hagen (1 shared paper)Jörg J. Möhrle (6 shared papers)Peter O’Rourke (5 shared papers)James McCarthy (6 shared papers)Louise Marquart (5 shared papers)Paul Griffin (4 shared papers)Rob Hooft van Huijsduijnen (3 shared papers)Stephan Duparc (3 shared papers)
Journals: Antimicrobial Agents and Chemotherapy (3 papers)Malaria Journal (3 papers)Infectious Diseases and Therapy (2 papers)Journal of Pharmaceutical Sciences (1 paper)HIV Medicine (1 paper)
Partner nations: Switzerland United Kingdom United States

In The Last Decade

Mark Baker

21 papers receiving 738 citations

Peers

Countries citing papers authored by Mark Baker

Since Specialization

Citations

This map shows the geographic impact of Mark Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Baker more than expected).

Fields of papers citing papers by Mark Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Baker. The network helps show where Mark Baker may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Baker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Baker Line = papers co-authored together Mark Baker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial The Lancet Infectious Diseases ·Aung Pyae Phyo, Podjanee Jittamala, François Nosten, Sasithon Pukrittayakamee, Mallika Imwong, Nicholas J. White, Stephan Duparc, Fiona Macintyre, Mark Baker, Jörg J. Möhrle	2015	127
2	Skin penetration and tissue permeation after topical administration of diclofenac Current Medical Research and Opinion ·Martina Hagen, Mark Baker	2017	103
3	A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study Malaria Journal ·James McCarthy, Thomas Rückle, Elhadj Djeriou, Cathy Cantalloube, Daniel Ter-Minassian, Mark Baker, Peter O’Rourke, Paul Griffin, Louise Marquart, Rob Hooft van Huijsduijnen, Jörg J. Möhrle	2016	81
4	Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake Xenobiotica ·Mark Baker, Ted A.H. Parton	2007	72
5	Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis Nature Communications ·Lucy Okell, Matthew Cairns, Jamie T. Griffin, Neil M. Ferguson, Joel Tärning, George Jagoe, Pierre Hugo, Mark Baker, Umberto D’Alessandro, Teun Bousema, David Ubben, Azra C. Ghani	2014	71
6	Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers Journal of Antimicrobial Chemotherapy ·James McCarthy, Mark Baker, Peter O’Rourke, Louise Marquart, Paul Griffin, Rob Hooft van Huijsduijnen, Jörg J. Möhrle	2016	51
7	Piperaquine Monotherapy of Drug-SusceptiblePlasmodium falciparumInfection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia The Journal of Infectious Diseases ·Cielo Pasay, Rebecca J. Rockett, Silvana Sekuloski, Paul Griffin, Louise Marquart, Christopher L. Peatey, Claire Wang, Peter O’Rourke, Suzanne Elliott, Mark Baker, Jörg J. Möhrle, James McCarthy	2016	48
8	Evaluating the Pharmacodynamic Effect of Antimalarial Drugs in Clinical Trials by Quantitative PCR Antimicrobial Agents and Chemotherapy ·Louise Marquart, Mark Baker, Peter O’Rourke, James McCarthy	2015	35
9	Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials HIV Medicine ·Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D’Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari	2022	32
10	Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects British Journal of Clinical Pharmacology ·Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy Moore, Ciara Seal, Amy Cutrell, Ronald D’Amico, Paul Benn, Raphael J. Landovitz, Mark A. Marzinke, William Spreen, Susan L. Ford	2022	32
11	Prediction of Plasma Protein Binding Displacement and its Implications for Quantitative Assessment of Metabolic Drug–Drug Interactions from In Vitro Data Journal of Pharmaceutical Sciences ·Hege Christensen, Mark Baker, Geoffrey T. Tucker, Amin Rostami‐Hodjegan	2006	29
12	Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development Antimicrobial Agents and Chemotherapy ·James McCarthy, Louise Marquart, Silvana Sekuloski, Katharine R. Trenholme, Suzanne Elliott, Paul Griffin, Rebecca J. Rockett, Peter O’Rourke, Theo P. Sloots, Íñigo Angulo‐Barturen, Santiago Ferrer, Marı́a Belén Jiménez-Dı́az, María-Santos Martínez, Rob Hooft van Huijsduijnen, Stephan Duparc, Didier Leroy, Timothy N. C. Wells, Mark Baker, Jörg J. Möhrle	2016	28
13	Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers European Journal of Drug Metabolism and Pharmacokinetics ·Carrie A. Morris, Stephen R. Dueker, Peter N. Lohstroh, Liquan Wang, Xinping Fang, Donald Jung, Luis López Lázaro, Mark Baker, Stephan Duparc, Isabelle Borghini-Fuhrer, Rolf Pokorny, Jangsik Shin, Lawrence Fleckenstein	2014	14
14	A comparison of the duration of post-treatment protection of artemether-lumefantrine, dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated malaria Malaria Journal ·(unknown), Michael T. Bretscher, Jamie T. Griffin, Pierre Hugo, Mark Baker, Azra C. Ghani, Lucy Okell	2014	14
15	Lacosamide efficacy and tolerability in clinical practice – Post marketing analysis from a single dedicated epilepsy center Clinical Neurology and Neurosurgery ·Mark Baker, Bassel Abou‐Khalil, Amir Arain, Pavan Tummala, Nabil J. Azar, Kevin F. Haas, Hasan H. Sonmezturk	2018	5
16	Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria Antimicrobial Agents and Chemotherapy ·Thanaporn Wattanakul, Mark Baker, J. Möhrle, Brett McWhinney, Richard M. Hoglund, James McCarthy, Joel Tärning	2021	4
17	Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine Therapeutic Advances in Infectious Disease ·Parul Patel, Paula Teichner, Emilie R Elliot, Marta Boffito, Milena Murray, Joseph W. Polli, Mark Baker, Susan L. Ford, Kelong Han, Alberto Russu, Herta Crauwels, Ronald D’Amico, William Spreen, Jean van Wyk	2023	4
18	Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV Infectious Diseases and Therapy ·Nilay Thakkar, Rulan Griesel, Amy Pierce, Veronica Bainbridge, Bronagh Shepherd, Konstantinos Angelis, Andrew R. Tomlinson, Yash Gandhi, Darin Brimhall, David Anderson, Susan Andrews, Carolina Acuipil, Cynthia McCoig, Mark Baker, Paul Benn	2025	2
19	Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV Infectious Diseases and Therapy ·Nilay Thakkar, Rulan Griesel, Amy Pierce, Veronica Bainbridge, Bronagh Shepherd, Konstantinos Angelis, Andrew R. Tomlinson, Yash Gandhi, Darin Brimhall, Brian Spears, David Anderson, Emma Pinnick, Carolina Acuipil, Cynthia McCoig, Mark Baker, Paul Benn	2025	2
20	Lost in translation? Bridging the preclinical / clinical divide Malaria Journal ·Mark Baker, Jörg J. Möhrle, Daren Austin	2012	2

About Mark Baker

Mark Baker is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases, Oncology, Computational Theory and Mathematics and Virology, having authored 22 papers that have together received 757 indexed citations. Recurring topics across this work include Malaria Research and Control (10 papers), HIV/AIDS drug development and treatment (6 papers), Computational Drug Discovery Methods (5 papers), HIV/AIDS Research and Interventions (5 papers), Drug Transport and Resistance Mechanisms (5 papers), HIV Research and Treatment (4 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Drug-Induced Hepatotoxicity and Protection (2 papers). The work is most often cited by research in Pharmacology (141 citations), Public Health, Environmental and Occupational Health (403 citations), Computational Theory and Mathematics (155 citations), Pharmaceutical Science (59 citations) and Virology (45 citations). Mark Baker has collaborated with scholars based in Switzerland, United Kingdom and United States. Frequent co-authors include Martina Hagen, Jörg J. Möhrle, Peter O’Rourke, James McCarthy, Louise Marquart, Paul Griffin, Rob Hooft van Huijsduijnen, Stephan Duparc, Mallika Imwong and Fiona Macintyre. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Malaria Journal, Infectious Diseases and Therapy, Journal of Pharmaceutical Sciences and HIV Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact